These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28279563)

  • 41. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.
    Zhang AJ; Li C; To KK; Zhu HS; Lee AC; Li CG; Chan JF; Hung IF; Yuen KY
    Clin Vaccine Immunol; 2014 Apr; 21(4):570-9. PubMed ID: 24521786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection.
    Honda-Okubo Y; Ong CH; Petrovsky N
    Vaccine; 2015 Sep; 33(38):4892-900. PubMed ID: 26232344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.
    Martínez-Gil L; Goff PH; Hai R; García-Sastre A; Shaw ML; Palese P
    J Virol; 2013 Feb; 87(3):1290-300. PubMed ID: 23175362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.
    Lee TY; Kim CU; Bae EH; Seo SH; Jeong DG; Yoon SW; Chang KT; Kim YS; Kim SH; Kim DJ
    Vaccine; 2017 Jan; 35(4):586-595. PubMed ID: 28024958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical evaluation of the efficacy of an H5N8 vaccine candidate (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness.
    Jeong JH; Kim EH; Lloren KKS; Kwon JJ; Kwon HI; Ahn SJ; Kim YI; Choi WS; Si YJ; Lee OJ; Han HJ; Baek YH; Song MS; Choi YK; Kim CJ
    Vaccine; 2019 Jan; 37(3):484-493. PubMed ID: 30502069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
    Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
    J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.
    Luke JM; Simon GG; Söderholm J; Errett JS; August JT; Gale M; Hodgson CP; Williams JA
    J Virol; 2011 Feb; 85(3):1370-83. PubMed ID: 21106745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A
    Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of a robust immune response against avian influenza virus following transdermal inoculation with H5-DNA vaccine formulated in modified dendrimer-based delivery system in mouse model.
    Bahadoran A; Ebrahimi M; Yeap SK; Safi N; Moeini H; Hair-Bejo M; Hussein MZ; Omar AR
    Int J Nanomedicine; 2017; 12():8573-8585. PubMed ID: 29270010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retinoic Acid-Inducible Gene I-Like Receptors Activate Snail To Limit RNA Viral Infections.
    Vedagiri D; Gupta D; Mishra A; Krishna G; Bhaskar M; Sah V; Basu A; Nayak D; Kalia M; Valiya Veettil M; Harshan KH
    J Virol; 2021 Oct; 95(21):e0121621. PubMed ID: 34379517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
    Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
    Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RIG-I Signaling Is Essential for Influenza B Virus-Induced Rapid Interferon Gene Expression.
    Mäkelä SM; Österlund P; Westenius V; Latvala S; Diamond MS; Gale M; Julkunen I
    J Virol; 2015 Dec; 89(23):12014-25. PubMed ID: 26378160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.